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Abstract
Beta-thalassemia major (BTM) is a hereditary hemoglobinopathy, characterized by
anemia, increased free radicals and iron overload which can lead to hyperferritinemia,
glomerular injury, and kidney dysfunction. This research aimed to analyze the
association between hyperferritinemia and urinary podocalyxin (uPCX) as the indicator
of glomerular injury in BTM. This retrospective cohort study was conducted on 60 BTM
patients aged ≤18 years who came to the pediatrics unit of Dr. Moewardi Hospital
Surakarta from April to May 2017. The data were analyzed to determine relative risk
and 95%CI for each variable, followed by multivariate analysis with logistic regression.
The prevalence of elevated uPCX in BTM patients in this research was 50%. The results
showed an association of hyperferritinemia (RR2.51, 95%CI 1.28-4.93, p=0.002), the
degree of anemia(RR2.00, 95%CI 1.14-3.52, p=0.01), the number of transfusion (RR
1.75, 95%CI 1.09-2.82, p=0.028), the duration of transfusion (RR 1.83, 95%CI 0.98-3.42,
p=0.035), the duration of illness (RR 1.60, 95%CI 0.95-2.72, p=0.071) and the duration
of iron chelation therapy (RR 1.58,95%CI 0.79-3.17, p=0.152) with glomerular injury. The
multivariate analysis showed that hyperferritinemia and degree of anemia remained
significantly associated with glomerular injury (RR 5.46; 95%CI 1.30-23.01; p=0.021 and
RR 4.13; 95%CI 1.15-14.85; p=0.030). This study demonstrates a statistically significant
association between hyperferritinemia, the degree of anemia, the number of transfusion
and the duration of transfusion with kidney injury in BTM patients. Routine monitoring
of renal function in BTM is recommended.
Keywords: Beta-thalassemia major, hyperferritinemia, urinary podocalyxin, glomerular
injury
1. Introduction
Beta thalassemia major (BTM) is a genetic disorder characterized by absence (β0) or
decrease (β+) of β globin chain synthesis of hemoglobin [1]. Thalassemia is the most
common genetic disorder, it is estimated that 60000 babies are born with thalassemia
every year. In 2001, WHO reported that 7% of the worldwide population was thalassemia
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carrier, with the highest incidence was 40% in Asia and 55 million people were South
East Asians. In Indonesia, 3-8% people are thalassemia carrier, and in some areas, it
reached 10%. It is estimated that annually 3000 newborns are thalassemia carriers [5].
There has not been any medicine that can cure BTM until now. Blood transfusion
every 2-4 weeks is the only therapy for anemia in thalassemia patients. This continu-
ous transfusion can result in iron overload in many organs, such as heart, liver, kidney,
endocrine organs and others. Organ dysfunction is seen in children over 5 years old
receiving transfusion. The accumulation of free iron (ferrous iron/Fe2+) can come across
Fenton reaction which formed free radicals leading to oxidative stress which will oxidize
lipid membrane of the cells (lipid peroxidation) and nucleic acid modification, caused
cell death, tissue damage and eventually organ damage [6–8].
The prevalence of kidney disease in BTM patients receiving ≥ 6 units of a packed
red cell (PRC) in Indonesia is 78.6% [9]. It is reported that albuminuria found in 56%
BTM patients [10]. Non-progressive increase of creatinine occurred in 10% BTM patients
receiving deferasirox [11].
Albuminuria, defined as urinary albumin to creatinine ratio (UACR), expresses an
increased of glomerular endothelial permeability. It is also a general marker of endothe-
lial dysfunction [12, 13]. Urinary albumin to creatinine ratio has a limitation, as it is a
repeated examination. This test also influenced by sex, age, urinary tract infection, high
protein diet and acute fever [14, 15]. Podocyturia, caused by glomerular podocyte dam-
age, can be assessed using one of the specific markers of podocyte, called podocalyxin.
Podocyturia is a subclinical marker that can be detected prior to proteinuria [16]. This
is the first study using urinary podocalyxin (uPCX) as a marker for glomerular injury in
BTM.
This study aimed to assess the association between hyperferritinemia and other fac-
tors affecting the glomerular injury in BTM patients, which is characterized by increased
urinary podocalyxin (uPCX) due to oxidative stress induced by hyperferritinemia.
2. Methods
This retrospective cohort study was carried out in the Pediatric Department and Clini-
cal Laboratory Department of Moewardi Hospital at Surakarta, Central Java, Indonesia
between April and May 2017. The study participants were 60 patients aged ≤18 years
old, who were clinically diagnosed with BTM receiving routine transfusion for more than
1 year or>10 units of blood transfusion and the parents agreed their children be enrolled
in the study by signing informed consent. The exclusion criteria were the history of
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liver and kidney disease other than due to BTM natural clinical course or BTM therapy,
infection or acute inflammation and urinary tract infection (UTI).
History taking and review of medical records were performed before blood sampling
to obtain patient identity, duration of illness, history of transfusion and chelation therapy.
Laboratory data were taken from medical records to find out the history of ferritin level,
complete blood count, creatinine and liver transaminases during a previous year before
this study.
Urine containers were given to the parents to be filled in the next morning. 10 mL of
the urine was taken as a sample. The first 5 ml was used for routine analysis (automated
urinalyzer Sysmex UX 2000) and urine creatinine (automated chemistry analyzer Advia-
1800). The rest 5 mL was then centrifuged at 1000 g for 15 minutes. The supernatant was
taken into aliquot and stored at -80∘C until analysis for uPCX by ELISA (enzyme-linked
immunosorbent assay) using human PCX ELISA kit from E-Labscience USA. The result
of uPCX was reported as uPCX to urine creatinine ratio.
Ethical clearance was obtained from the biomedical research ethics committee of
the Medical Faculty of Universitas Sebelas Maret and Moewardi Hospital at Surakarta.
Informed consent was obtained from all parents subjects.
Data were tested for normal distribution using the Kolmogorov–Smirnov. Participants’
characteristics were presented using means ± SD or median and min-max for continu-
ous variables and frequencies for categorical variables. Variables normally distributed
were compared by independent t-test, variables not normally distributedwere compared
using Chi-Square and Fisher Exact-test. We applied bivariate and multivariate logistic
regression analysis to estimate the effects of hyperferritinemia and other variables on
glomerular injury in BTM. The analysis was performed by SPSS statistical software pack-
age program version 23, p-value < 0.05 was considered significant.
3. Result
The subjects of this study were comprised of 34 boys (56.7%) and 26 girls (43.3%), the
mean age was 10.73±4,22 years old and the average age of receiving transfusion was
84.37±47.97months. Pretransfusion hemoglobin level was 7.92±0.68mg/dL. All subjects
have eGFR of more than 110 mL/min/1.73m2.
Thirty-four subjects (56.7%) had a ferritin level of ≥2500 ng/mL in one year prior
to the study. Median [minimum–maximum] of the ferritin level, the duration of illness,
the amount of transfusion in the previous year, the duration of chelating therapy and
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uPCX level were 2257.10 (713.40-8988.20) ng/mL; 69.5 (11.0-211.0) months; 24.0 (12.0-
42.0) units/year; 48.0 (0.0-198.0) months and 123.0 (5.76-3019.13) ng/mmol urine creati-
nine, respectively. Based on the uPCX level (≥126 ng/mmol urine creatinine and <126
ng/mmol urine creatinine), the subjects were categorized into two groups, i.e with and
without glomerular injury, each of them comprised of 30 subjects (50%).
Comparison between groups with and without glomerular injury showed significant
difference in frequency of hyperferritinemia episode in previous year, mean of serum
ferritin, duration of transfusion, number of transfusion, duration of chelation therapy,
and an average of hemoglobin level prior to transfusion (p=0.002; p=0.000; p=0.013;
p=0.004; p=0.023 and p=0.002, respectively), age and duration of illness did not differ
significantly between two groups (p=0.430 and p=0123, respectively). Demographic and
biochemistry characteristics of the subjects have been summarized in Table 1.
Bivariate analysis between hyperferritinemia and other factors affecting glomerular
injury were presented in Table 2. Hyperferritinemia (serum ferritin ≥2500 ng/mL) was a
risk factor of glomerular injury in BTM patients with a relative risk (RR) of 2.51 (95% CI
1.28-4.93; p=0.002).
Relative risk and 95%CI of other variables affecting glomerular injury such as severity
of anemia, amount of transfusion per year, duration of transfusion, duration of illness and
duration of chelation therapy were 2.00 (95%CI 1.14-3.52; p= 0.01); 1.75 (95%CI: 1.09-2.82;
p= 0.028); 1.83 (95%CI: 0.98-3.42; p= 0.035); 1.60 (95%CI: 0.95-2.72; p= 0.071) and 1.58
(95%CI: 0.9-3.17; p= 0.152, respectively).
Multivariate analysis was demonstrated with adjustment on the severity of anemia
(Table 3, model 1), both variables showed significant association with a glomerular injury
with RR of 5.68 (95% CI 1.72–18.71; p=0.004) and RR of 4.00 (95% CI 1.24–12.93; p=0.021),
respectively. With adjustment on duration of transfusion (model 2), amount of transfusion
and duration of transfusion (model 3), amount of transfusion, duration of transfusion and
duration of illness (model 4), amount of transfusion, duration of transfusion, duration of
illness and duration of chelation (model 5), hyperferritinemia and severity of anemia still
demonstrated significant association with glomerular injury. The strength of association
between hyperferritinemia and severity of anemia with a glomerular injury after adjust-
ment with other variables were RR 5.46 (95% CI: 1.30–23.01; p=0.021) and 4.13 (95% CI:
1.15–14.85; p=0.030), respectively. Multivariate analysis between hyperferritinemia and
other factors affecting glomerular injury were presented in Table 3.
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Age (years) 10.73 ± 4.22𝑎 10.29 ± 4.24𝑎 11.16 ± 4.22𝑎 0.43
Sex (%)𝑐 0.602
Boys 26 (43.3) 14 (46.67) 12 (40.00)
Girls 34 (56.7) 16 (53.33) 18 (60.00)
Chelating agent (%)𝑐 0.056
Deferoxamine 2 (3.3) 0 (0) 2 (6.67)
Deferiprone 49 (81.7) 28 (93.33) 21 (70.00)
Deferasirox 9 (15) 2 (6.67) 7 (23.33)
Splenectomy (%)𝑐 1
Yes 5 (8.3) 3 (10) 2 (6.67)
No 55 (91.7) 27 (90) 28 (93.33)
Family history (%)𝑐 1
Yes 18 (30) 9 (30) 9 (30)
No 42 (70) 21 (70) 21 (70)
Hyperferritinemia (%)𝑐 0.002*
Yes 34 (56.7) 11 (36.67) 23 (76.67)
No 26 (43.3) 19 (63.33) 7 (23.33)









Duration of illness (months) 69.5 (110-211.0)𝑏 70.17 ± 44.75𝑎 89.27 ± 49.60𝑎 0.123
Duration of transfusion
(months)
84.37 ± 47.97𝑎 69.27 ± 41.80𝑎 99.47 ± 49.65𝑎 0.013*
Unit of transfusion
(unit/year)
24.0 (12.0-42.0)𝑏 24.0 (12.0-36.0)𝑏 24.0 (12.0-42.0)𝑏 0.004*
Duration of chelation
(months)
48.0 (0.0-198.0)𝑏 48.70 ± 42.00𝑎 75.70 ± 47.10 𝑎 0.023*





67.27 ± 37.99𝑎 431.28 ± 587.70𝑎 0.002*
𝑎 data normally distributed (mean ± SD), independent t-test
𝑏 data not normally distributed [median (minimum-maximum)] categorical data [frequency (%)], Chi-
square or Fisher-Exact test
∗ p significantif < 0.05.
4. Discussion
This study involved 60 patients with BTM, in which glomerular injury based on a uPCX
level of ≥126 ng/mmol urine creatinine occurred in 50% subjects. This demonstrated
that half of the BTM patients suffered from glomerular injury. Kidney damage in BTM is
caused by multifactorial, such as iron overload, severe chronic anemia, chronic hypoxia
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*p significant if< 0,05
and nephrotoxicity effect of iron chelation therapy. Those processes result in free rad-
icals formation, causing oxidative stress which will oxidize lipid of the cell membrane
(lipid peroxidation) and protein compound of the cell leading to cell damage and cell
death, which eventually ends with organ damage, including kidney [17, 18].
Glomerular hypoxia can result in increased activation of protein kinase-C (PKC), intra-
cellular calcium, decreased nitric oxide, increased of endothelin and increased of trans-
forming growth factor-β1 (TGF-β1) which activate fibroblast, changing extracellular matrix
metabolism in glomerular cells and fibrogenesis [19, 20].
Glomerular filtration barrier consists of 3 layers, i.e endothelial cells covered by gly-
coprotein with negative charges, glomerular basement membrane (GBM) in the middle,
and epithelial cell named podocyte attached on GBM [21]. Podocyte is a visceral epithe-
lial cell of the kidney, together with GBM and endothelial cell, will ensure the selective
permeability of the glomerular filtration barrier. One of the protein compounds of the
apical membrane domain located in the luminal side of the urinary space is podoca-
lyxin(PCX). Loss of glomerular visceral cells was associated with glomerular sclerosis
and loss of kidney function [22, 23]. Perturbation on filtration slit or podocyte injury
can trigger massive proteinuria. Podocalyxin, as expressed on the apical membrane
of podocyte, was shed directly into urine as a result of podocyte injury, thus urinary
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Table 3: Multivariate analysis among hyperferritinemia and other factors affecting glomerular injury.
RR 95%CI p
Model 1
Hyperferritinemia 5.68 1.72 – 18.71 0.004*
Severity of anemia 4 1.24 – 12.93 0.021*
Model 2
Hyperferritinemia 5.01 1.49 – 16.83 0.009*
Severity of anemia 3.63 1.10 – 11.96 0.034*
Duration of transfusion 1.99 0.59 – 6.70 0.266
Model 3
Hyperferritinemia 4.01 1.12 – 14.41 0.033*
Severity of anemia 3.73 1.12 – 12.50 0.033*
Amount of transfusion 1.98 0.50 – 7.87 0.334
Duration of transfusion 1,85 0.54 – 6.34 0.331
Model 4
Hyperferritinemia 4.87 1.21 – 19.50 0.026*
Severity of anemia 4.29 1.20 – 15.33 0.025*
Amount of transfusion 1.98 0.93 – 7.97 0.335
Duration of transfusion 2.85 0.56 – 14.37 0.206
Duration of illness 2.85 0.36 – 11.74 0.414
Model 5
Hyperferritinemia 5.46 1.30 – 23.01 0.021*
Severity of anemia 4.13 1.15 – 14.85 0.030*
Duration of chelation 1.78 0.36 – 8.84 0.481
Amount of transfusion 1.96 0.49 – 7.89 0.341
Duration of transfusion 2.6 0.51 – 13.11 0.248
Duration of illness 2.55 0.41 – 15.83 0.314
* p significant if <0.05
podocalyxin poses as a subclinical marker of glomerular damage prior to albuminuria
[24].
Hara et al reported a significant increase in uPCX in diabetic patients with normoal-
buminuria [25]. Mohamed et al obtained a significant positive correlation between
uPCX and albuminuria. Urinary PCX was a risk factor for microalbuminuria and diabetic
nephropathy [25, 26].
Blood transfusion along with iron chelation either single or combination increases the
survival rate of BTM patients. This raises the manifestation of various organ dysfunction
as complications of BTM due to iron overload, including kidney dysfunction. There are
many observations on BTM complications on various organs, but very little monitoring
in kidney complication. Prevalence of kidney dysfunction in this study is nearly similar
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to that of Quinn et al [27] and Wirawan et al [9] which are 59% and 78.6%, respectively.
Lower prevalence (18.5%) was reported by Lai et al [28]. This difference is due to the
site of the studies, the age of subjects, therapeutic protocol, the amount of transfusion,
dosage and adherence to iron chelation therapy and the determination method of kid-
ney dysfunction.
In this study, there was a significant difference of the median of serum ferritin level
between two groups, however, a single measurement of serum ferritin cannot be used
as an independent predictor of kidney dysfunction, neither glomerular or tubular. Serum
ferritin is unable to represent the severity of tissue hemosiderosis. It is believed that
kidney damage results from iron overload, but this can not be assessed with a single
measurement of serum ferritin [27, 28].
More than half of our subjects (56.7%) experienced a history of hyperferritinemia
with serum level of ≥2500 ng/mL. Priyantiningsih [29] reported in 6 months monitoring
after DFX therapy, ferritin level found remained high. This study found that a history of
hyperferritinemia (serum ferritin of ≥2500 ng/mL) has a significant association with a
glomerular injury with RR=2.51; 95% 1.28-4.93; p=0.002).
Severe and recurrent anemia can result in tissue hypoxemia and increased oxidative
stress. Recurrent anemia also causes decreased vascular resistance, increased renal
blood flow and hyperfiltration, as showed in this study, all subjects have eGFR of more
than 110 mL/min/1.73m2. These changes precipitate glomerular capillary wall stretching,
endothelial and epithelial damage, along with transudation of a macromolecule into
mesangium. Prolonged hyperfiltration promotes the impaired function of the glomerulus
[27, 28, 30]. This study found that the severity of anemia is an independent risk factor
for glomerular injury.
Hemoglobin level should bemaintained for a range of 9.5-10.5 g/dl in order tomaintain
growth and development in normal range until the age of 10-11, however over that age, a
complication may occur due to iron overload and chronic anemia. Gokce et al [31] found
that BTM patients with glomerular hyperfiltration had a median hemoglobin level of 8.6
g/dL (7,6-10,5 g/dL). This hemoglobin range cannot be extrapolated in all health facilities
as it depends on individual health center protocol and availability of local resources.
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5. Conclusion
This study exhibits the association between hyperferritinemia with a glomerular injury
in BTM patients. In addition to hyperferritinemia, the severity of anemia is also an inde-
pendent risk factor. Routine monitoring of renal function in BTM patients is highly rec-
ommended.
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